N/A N=70 Anti-inflammatory Steroids in the Prevention of Tooth Sensitivity
Inflammation
Primary: Visual Analogic Scale (0-100) for Tooth Sensibility. — 6.31; 11.14 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=73 Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
Prostate Cancer
Primary: Cohort 1 - Number of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Response Rate) — 1 Participants
Phase 2 N=40 Stroke and CPAP Outcome Study: A Sham-controlled Trial of CPAP Among Stroke Rehabilitation Patients
Stroke · Sleep Apnea, Obstructive
Primary: Feasibility of Enrolling Eligible Stroke Patients Admitted to Inpatient Rehabilitation for an Acute Ischemic or Hemorrhagic Stroke Into a Pilot, Randomized Clinical…
Phase 2 N=66 Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches
Systemic Lupus Erythematosus
Primary: British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA) — 8; 8 Participants — p=>0.999
Phase 2 N=10 Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder
Primary: Change in Ohio Autism Clinical Impressions Scale - Improvement (OACIS-I) Average Score From Baseline — 0.28; 0.28; 0.28; 0.33 score on a scale
Phase 1 N=60 Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma
Glaucoma
Primary: Incidence of Events as of Primary Safety Outcomes — 0; 2; 0; 0 Number of events
Phase 2 N=99 Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
Prostate Cancer
Primary: 2-year Metastasis-Free Survival Rate — 42.3; 41.8 percent probability — p=0.97
Phase 2 N=271 Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
Hypogonadotropic Hypogonadism
Primary: Percentage of Patients With Normalised Testosterone After 24 Weeks of Study Treatment — 59; 62; 63; 7 Participants
N/A N=42 Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
Mild Cognitive Impairment · Alzheimer Disease · Vascular Dementia
Primary: Percentage of Recruited Subjects Able to Comply With the Protocol — 12; 13; 3; 14 Participants
N/A N=20 Evaluating the Safety and Efficacy of the Pico Laser With a Specialized Lens Array for the Treatment of Wrinkles
Wrinkles
Primary: Photographic Evaluation of Wrinkle Severity at Baseline — 5.25 score on a scale
N/A N=144 Joyful Parenting Pilot Project RCT Study
Mental Well-being · Happiness
Primary: Sharing (Praise), Mind (Appreciation) and Enjoyment (SME) Related Behaviours — 11.49; 11.34; 12.23; 11.05 score on a scale
Phase 3 N=1,346 Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Multiple Sclerosis
Primary: Adjusted Annualized Relapse Rate (ARR) During the Treatment Period — 0.350; 0.241; 0.181 relapses/year — p=<0.0001
N/A N=21 Teaching Academic Success Skills to Students With Autism Spectrum Disorders in Clinical Setting
Autism Spectrum Disorder
Primary: Children's Organizational Skills Scale — 66.14; 57.24 T-Score
N/A N=80 Nitroglycerin Infusion During Cardiac Surgery
Lactic Acidosis · Blood Glucose, High
Primary: Plasma Lactate Level, Before Incision — 1.1; 1.0 mmol/L — p=0.618
N/A N=194 Sensor and Electronic Health Records (EHR) Integration Pilot Study
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) — -0.03; 0.07; -0.09; -0.08 Liter